WAVE Life Sciences Ltd. (NASDAQ:WVE) was the target of a significant growth in short interest during the month of September. As of September 15th, there was short interest totalling 2,078,053 shares, a growth of 27.9% from the August 31st total of 1,624,753 shares. Based on an average daily trading volume, of 120,961 shares, the days-to-cover ratio is presently 17.2 days. Currently, 11.9% of the company’s stock are short sold.

WAVE Life Sciences (NASDAQ WVE) opened at 22.00 on Tuesday. The stock’s market capitalization is $610.72 million. The company has a 50-day moving average of $21.45 and a 200-day moving average of $21.28. WAVE Life Sciences has a one year low of $15.15 and a one year high of $40.15.

WAVE Life Sciences (NASDAQ:WVE) last announced its quarterly earnings data on Wednesday, August 9th. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.14). WAVE Life Sciences had a negative net margin of 3,375.12% and a negative return on equity of 55.19%. The company had revenue of $0.68 million for the quarter, compared to analysts’ expectations of $0.73 million. On average, equities analysts forecast that WAVE Life Sciences will post ($3.71) EPS for the current fiscal year.

In other news, insider Michael A. Panzara sold 7,414 shares of the stock in a transaction on Wednesday, July 12th. The stock was sold at an average price of $16.67, for a total value of $123,591.38. Following the sale, the insider now directly owns 15,336 shares of the company’s stock, valued at $255,651.12. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Masaharu Tanaka sold 20,747 shares of the stock in a transaction on Monday, September 18th. The stock was sold at an average price of $24.21, for a total value of $502,284.87. The disclosure for this sale can be found here. 53.00% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. Sabby Management LLC purchased a new stake in WAVE Life Sciences during the 2nd quarter valued at about $2,636,000. California State Teachers Retirement System increased its holdings in shares of WAVE Life Sciences by 43.8% in the second quarter. California State Teachers Retirement System now owns 21,009 shares of the company’s stock valued at $391,000 after purchasing an additional 6,400 shares during the period. The Manufacturers Life Insurance Company increased its holdings in shares of WAVE Life Sciences by 71.0% in the second quarter. The Manufacturers Life Insurance Company now owns 9,422 shares of the company’s stock valued at $175,000 after purchasing an additional 3,912 shares during the period. Redmile Group LLC increased its holdings in shares of WAVE Life Sciences by 75.0% in the second quarter. Redmile Group LLC now owns 2,224,407 shares of the company’s stock valued at $41,374,000 after purchasing an additional 953,310 shares during the period. Finally, State Street Corp increased its holdings in shares of WAVE Life Sciences by 26.6% in the second quarter. State Street Corp now owns 151,241 shares of the company’s stock valued at $2,815,000 after purchasing an additional 31,743 shares during the period. 69.58% of the stock is owned by institutional investors.

Several equities analysts have recently weighed in on the company. Mizuho set a $34.00 price target on WAVE Life Sciences and gave the stock a “buy” rating in a research report on Friday, August 18th. Jefferies Group LLC reiterated a “buy” rating and issued a $40.00 price target (down previously from $42.00) on shares of WAVE Life Sciences in a research note on Thursday, August 10th. BidaskClub upgraded shares of WAVE Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, August 26th. JMP Securities reissued an “outperform” rating and set a $40.00 price objective on shares of WAVE Life Sciences in a research report on Friday, June 9th. Finally, Zacks Investment Research downgraded shares of WAVE Life Sciences from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $40.00.

WARNING: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/10/03/wave-life-sciences-ltd-wve-short-interest-up-27-9-in-september.html.

WAVE Life Sciences Company Profile

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Receive News & Stock Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related stocks with our FREE daily email newsletter.